Abazistobart

阿巴苏拜单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAbazistobart
Drug Alias Name重组抗PD-1人源化单克隆抗体注射液Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian)重组抗PD-1人源化单克隆抗体（三生国健）SSGJ-609ASSGJ-609-A +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursBreast NeoplasmsSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSyncromune IncSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursBreast NeoplasmsSarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A